Abstract Library

#4251 Upfront Oxaliplatin–Fluoropyrimidine chemotherapy and Somatostatin Analogues (SSA) in advanced well-differentiated G2/G3 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are frequently diagnosed at advanced stage. For well-differentiated somatostatin receptor-positive (SSTR +) NETs, somatostatin analogues (SSAs) are the preferred first-line therapy. However, in patients (pts) with G2/G3 and a high tumor burden, SSA alone might not be enough.

Conference:

Presenting Author:

Authors: Maratta M, Sparagna I, d'Agostino F, Occhipinti D, Raia S,

Keywords: gastroenteropancreatic NET, neuroendocrine tumor, chemotherapy, conversion surgery, neoadjuvant treatment,

#4115 Neoadjuvant PRRT with 90Y-DOTATOC: Preliminary results from a monocentric perspective study

Introduction: Surgery is considered the only curative treatment for pancreatic neuroendocrine tumors (pNETs), but it is feasible only in a few patients. A new possible strategy in pNETs is preoperative PRRT, as its cytoreductive effect could increase the efficacy of surgery.

Conference:

Presenting Author:

Authors: Barone A, Grana C, Papi S, Bertani E, Rocca P,

Keywords: PRRT, 90Y-DOTATOC, Neoadjuvant PRRT, pancreatic NET,

#4108 Clinical and epidemiological profile of neuroendocrine differentiation – A hospital-based retrospective study

Introduction: Global research on neuroendocrine differentiation (NED) in carcinomas remains limited, despite its distinct clinical features, disease progression, pathology, treatment outcomes, and poor prognosis. At the 2023 ENETS Conference, we presented our findings on NED in gastric cancer and colorectal cancer. However, more studies are essential to better comprehend NED's clinical and epidemiological aspects.

Conference:

Presenting Author:

Authors: Wen Y, Shi S,

Keywords: Neuroendocrine differentiation, breast cancer, lung cancer, esophageal cancer, prostate cancer,

#3880 Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium – Comparison of clinico-pathological and survival outcomes

Introduction: The role of peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment in patients with is still controversial, although recent experiences showed encouraging results in terms of oncological outcomes.

Conference:

Presenting Author: Genova L

Authors: Genova L, Andreasi V, Partelli S, Muffatti F, Battistella A,

Keywords: peptide receptor radionuclide therapy, prrt, neoadjuvant, surgery, yttrium, lutetium,

#3851 68Ga-DOTATOC PET radiomics as a novel preoperative predictive tool for PanNETs aggressiveness

Introduction: The knowledge of Pancreatic Neuroendocrine Tumors (PanNETs) features of aggressiveness before surgery is fundamental for an appropriate treatment planning.

Conference:

Presenting Author:

Authors: Mapelli P, Bezzi C, Ghezzo S, Muffatti F, Andreasi V,

Keywords: 68Ga-DOTATOC, NET, PET, radiomics,